Regulation of vascular smooth muscle cell migration and proliferation in vitro and in injured rat arteries by a synthetic matrix metalloproteinase inhibitor

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 16, Issue 1, 1996, Pages 28-33

  Zempo, Nobuya ^a   Koyama, Noriyuki ^a   Kenagy, Richard D ^a   Lea, Holly J ^a   Clowes, Alexander W ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

arterial injury; metalloproteinases; migration; rats; smooth muscle cells

Indexed keywords

BATIMASTAT; COLLAGENASE; PLASMINOGEN; STROMELYSIN;

ANIMAL CELL; ANIMAL MODEL; ARTICLE; BASEMENT MEMBRANE; CELL MIGRATION; DNA SYNTHESIS; ENZYME ACTIVITY; ENZYME INHIBITION; HEART VENTRICLE REMODELING; NONHUMAN; PRIORITY JOURNAL; RAT; VASCULAR SMOOTH MUSCLE;

EID: 0030026574     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.16.1.28     Document Type: Article

References (69)

1. Clowes AW, Reidy MA, Clowes MM. Kinetics of cellular proliferation after arterial injury, I: smooth muscle growth in the absence of endothelium. Lab Invest. 1983;49:327-333.
2. Clowes AW, Schwartz SM. Significance of quiescent smooth muscle migration in the injured rat carotid artery. Circ Res. 1985;56:139-145.
3. Clowes AW, Clowes MM, Reidy MA. Kinetics of cellular proliferation after arterial injury, III: endothelial and smooth muscle growth in chronically denuded vessels. Lab Invest. 1986;54;295-303.
4. Clowes AW, Gown AM, Hanson SR, Reidy MA. Mechanisms of arterial graft failure, I: role of cellular proliferation in early healing of PTFE prostheses. Am J Pathol. 1985;118:43-54.
5. Clowes AW, Kirkman TR, Clowes MM. Mechanisms of arterial graft failure, II: chronic endothelial and smooth muscle cell proliferation in healing polytetrafluoroethylene prostheses. J Vasc Surg. 1986;3:877-884.
6. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature. 1993;362:801-809.
7. Ossowski L. Invasion of connective tissue by human carcinoma cell lines: requirement for urokinase, urokinase receptor, and interstitial collagenase. Cancer Res. 1992;52:6754-6760.
8. Stetler-Stevenson WG, Liotta LA, Kleiner DE Jr. Extracellular matrix 6: role of matrix metalloproteinases in tumor invasion and metastasis. FASEB J. 1993;7:1434-1441.
9. Kirchheimer JC, Remold HG. Endogenous receptor-bound urokinase mediates tissue invasion of human monocytes. J Immunol. 1989;143:2634-2639.
10. Matrisian LM, Gaire M, Rodgers WH, Osteen KG. Metalloproteinase expression and hormonal regulation during tissue remodeling in the cycling human endometrium. Contrib Nephrol. 1994;107:94-100.
11. Talhouk RS, Bissell MJ, Werb Z. Coordinated expression of extracellular matrix-degrading proteinases and their inhibitors regulates mammary epithelial function during involution. J Cell Biol. 1992; 118:1271-1282.
12. Galis ZS, Sukhova GK, Lark MW, Libby P. Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J Clin Invest. 1994;94:2493-2503.
13. Henney AM, Wakeley PR, Davies MJ, Foster K, Hembry R, Murphy G, Humphries S, Localization of stromelysin gene expression in atherosclerotic plaques by in situ hybridization. Proc Natl Acad Sci U S A. 1991;88:8154-8158.
14. Brown DL, Hibbs MS, Kearney M, Loushin C, Isner JM. Identification of 92-kD gelatinase in human coronary atherosclerotic lesions: association of active enzyme synthesis with unstable angina. Circulation. 1995;91:2125-2131.
15. Zempo N, Kenagy RD, Au YPT, Bendeck M, Clowes MM, Reidy MA, Clowes AW. Matrix metalloproteinases of vascular wall cells are increased in balloon-injured rat carotid artery. J Vasc Surg. 1994;20:209-217.
16. Bendeck MP, Zempo N, Clowes AW, Galardy RE, Reidy MA. Smooth muscle cell migration and matrix metalloproteinase expression after arterial injury in the rat. Circ Res. 1994;75:539-545.
17. Clowes AW, Clowes MM, Au YPT, Reidy MA, Belin D. Smooth muscle cells express urokinase during mitogenesis and tissue-type plasminogen activator during migration in injured rat carotid artery. Circ Res. 1990;67:61-67.
18. Kenagy RD, Hart C, Clowes AW. Role for growth factors and proteinases in the migration of smooth muscle cells through native extracellular matrix in vitro. FASEB J. 1993;7:A637.
19. Kenagy RD, Clowes AW. Primate smooth muscle cell migration from arterial explants depends on tissue plasminogen activator and urokinase activity. Circulation. 1995;92(suppl I):I-559. Abstract.
20. Nagase H, Enghild JJ, Suzuki K, Salveson G. Stepwise activation mechanisms of the precursor of matrix metalloproteinase 3 (stromelysin) by proteinases and (4-aminophenyl)mercuric acetate. Biochemistry. 1990;29:5783-5789.
21. Murphy G, Atkinson S, Ward R, Gavrilovic J, Reynolds JJ. The role of plasminogen activators in the regulation of connective tissue metalloproteinases. Ann N Y Acad Sci. 1992;667:1-12.
22. Davies B, Brown PD, East N, Crimmin MJ, Balkwill FR. A synthetic matrix metalloproteinase inhibitor decreases tumor burden and prolongs survival of mice bearing human ovarian carcinoma xenografts. Cancer Res. 1993;53:2087-2091.
23. Kelly JD, Haldeman BA, Grant FJ, Murray MJ, Seifert RA, Bowen-Pope DF, Cooper JA, Kazlauskas A. Platelet-derived growth factor (PDGF) stimulates PDGF receptor subunit dimerization and intersubunit trans-phosphorylation. J Biol Chem. 1991; 266:8987-8992.
24. Raines EW, Ross R. Platelet-derived growth factor. High yield purification and evidence for multiple forms. J Biol Chem. 1982;257: 5154-5160.
25. Koyama N, Harada K, Yamamoto A, Morisaki N, Saito Y, Yoshida S. Purification and characterization of an autocrine migration factor for vascular smooth muscle cells (SMC): SMC-derived migration factor. J Biol Chem. 1993;268:13301-13308.
26. Albini A, Iwamoto Y, Kleinman HK, Martin GR, Aaronson SA, Kozlowski JM, McEwan RN. A rapid in vitro assay for quantitating the invasive potential of tumor cells. Cancer Res. 1987;47:3239-3245.
27. Clowes AW, Reidy MA, Clowes MM. Mechanisms of stenosis after arterial injury. Lab Invest. 1983;49:208-215.
28. Hardonk MJ, Harms G. The use of 5′-bromodeoxyuridine in the study of cell proliferation. Acta Histochem Suppl. 1990;XXXIX: 99-108.
29. Good PI. Permutation Tests: A Practical Guide to Resampling Methods for Testing Hypotheses. New York, NY: Springer-Verlag; 1994:1.
30. Koyama N, Morisaki N, Saito Y, Yoshida S. Regulatory effects of platelet-derived growth factor-AA homodimer on migration of vascular smooth muscle cells. J Biol Chem. 1992;267:22806-22812.
31. Southgate KM, Davies M, Booth RFG, Newby AC. Involvement of extracellular-matrix-degrading metalloproteinases in rabbit aortic smooth-muscle cell proliferation. Biochem J. 1992;288:93-99.
32. Kenagy RD, Clowes AW. A possible role for MMP-2 and MMP-9 in the migration of primate arterial smooth muscle cells through native matrix. Ann NY Acad Sci. 1994;732:462-465.
33. Belkin VM, Belkin AM, Koteliansky VE. Human smooth muscle VLA-1 integrin: purification, substrate specificity, localization in aorta, and expression during development. J Cell Biol. 1990;111: 2159-2170.
34. Walker LN, Bowen-Pope DF, Reidy MA. Production of platelet-derived growth factor-like molecules by cultured arterial smooth muscle cells accompanies proliferation after arterial injury. Proc Natl Acad Sci U S A. 1986;83:7311-7315.
35. Grunwald J, Haudenschild CC. Intimal injury in vivo activates vascular smooth muscle cell migration and explant outgrowth in vitro. Arteriosclerosis. 1984;4:183-188.
36. Carey DJ. Control of growth and differentiation of vascular cells by extracellular matrix proteins. Annu Rev Physiol. 1991;53:161-177.
37. Buttle DJ, Handley CJ, Ilic MZ, Saklatvala J, Murata M, Barratt AJ. Inhibition of cartilage proteoglycan release by a specific inactivator of cathepsin B and an inhibitor of matrix metalloproteinases: evidence for two converging pathways of chondrocyte-mediated proteoglycan degradation. Arthritis Rheum. 1993;12:1709-1717.
38. Langille BL, O'Donnell F. Reductions in arterial diameter produced by chronic decreases in blood flow are endothelium-dependent. Science. 1986;231:405-407.
39. Kohler TR, Jawien A. Flow affects development of intimal hyperplasia after arterial injury in rats. Arterioscler Thromb. 1992;12: 963-971.
40. Zwolak RM, Adams MC, Clowes AW. Kinetics of vein graft hyperplasia: association with tangential stress. J Vasc Surg. 1987;5: 126-136.
41. Prescott MF, Sawyer WK, Von Linden-Reed J. Matrix metalloproteinase inhibitor-induced reduction of smooth muscle cell migration does not inhibit late lesion formation following ballooning. FASEB J. 1995;9:A855.
42. Pauly RR, Passaniti A, Bilato C, Monticone R, Cheng L, Papadopoulos N, Gluzband YA, Smith L, Weinstein C, Lakatta EG, Crow MT. Migration of cultured vascular smooth muscle cells through a basement membrane barrier requires type IV collagenase activity and is inhibited by cellular differentiation. Circ Res. 1994;75:41-54.
43. Wang X, Fu X, Brown PD, Crimmin MJ, Hoffman RM. Matrix metalloproteinase inhibitor BB-94 (batimastat) inhibits human colon tumor growth and spread in a patient-like orthotopic model in nude mice. Cancer Res. 1994;54:4726-4728.
44. Ohyama T, Fukuda K, Oda H, Nakamura H, Hikita Y. Substratum-bound elastin peptide inhibits aortic smooth muscle cell migration in vitro. Arteriosclerosis. 1987;7:593-598.
45. Koyama N, Seki J, Harlan JM, Clowes AW. Extracellular matrix regulates smooth muscle cell migration and contributes to the migration-inhibitory mechanism of PDGF-AA. Circulation. 1994;90(suppl I):I-637. Abstract.
46. Werb Z, Tremble P, Damsky CH. Regulation of extracellular matrix degradation by cell-extracellular matrix interactions. Cell Differ Dev. 1990;32:299-306.
47. Shapiro SD, Kobayashi DK, Pentland AP, Welgus HG. Induction of macrophage metalloproteinases by extracellular matrix: evidence for enzyme- and substrate-specific responses involving prostaglandin-dependent mechanisms. J Biol Chem. 1993;268:8170-8175.
48. Saarialho-Kere UK, Kovacs SO, Pentland AP, Olerud JE, Welgus HG, Parks WC. Cell-matrix interactions modulate interstitial collagenase expression by human keratinocytes actively involved in wound healing. J Clin Invest. 1993;92:2858-2866.
49. Tremble P, Chiquet-Ehrismann R, Werb Z. The extracellular matrix ligands fibronectin and tenascin collaborate in regulating collagenase gene expression in fibroblasts. Mol Biol Cell. 1994;5: 439-453.
50. Larjava H, Lyons JG, Salo T, Makela M, Koivisto L, Birkedal-Hansen H, Akiyama SK, Yamada KM, Heino J. Anti-integrin anti- bodies induce type IV collagenase expression in keratinocytes. J Cell Physiol. 1993;157:190-200.
51. 1 integrins during human melanoma cell invasion. Cancer Res. 1993;53:3411-3415.
52. Romanic AM, Madri JA. The induction of 72-kD gelatinase in T cells upon adhesion to endothelial cells is VCAM-1 dependent. J Cell Biol. 1994;125:1165-1178.
53. Matrisian LM. Metalloproteinases and their inhibitors in matrix remodeling. Trends Genet. 1990;6:121-125.
54. Woessner JF Jr. Matrix metalloproteinases and their inhibitors in connective tissue remodeling. FASEB J. 1991;5:2145-2154.
55. Rifkin DB, Tsuboi R, Mignatti P. The role of proteases in matrix breakdown during cellular invasion. Am Rev Respir Dis. 1989;140:1112-1113.
56. Scully MF. Plasminogen activator-dependent pericellular proteolysis. Br J Haematol. 1991;79:537-543.
57. Stetler-Stevenson WG. Type IV collagenases in tumor invasion and metastasis. Cancer Metastasis Rev. 1990;9:289-303.
58. McDonnell S, Matrisian LM. Stromelysin in tumor progression and metastasis. Cancer Metastasis Rev. 1990;9:305-319.
59. Kalebic T, Garbisa S, Glaser B, Liotta LA. Basement membrane collagen: degradation by migrating endothelial cells. Science. 1983; 221:281-283.
60. Herron GS, Werb Z, Dwyer K, Banda MJ. Secretion of metalloproteinases by stimulated capillary endothelial cells. J Biol Chem. 1986;261:2810-2813.
61. Schultz RM, Silberman S, Persky B, Bajkowski AS, Carmichael DF. Inhibition by human recombinant tissue inhibitor of metalloproteinases of human amnion invasion and lung colonization by murine B16-F10 melanoma cells. Cancer Res. 1988;48:5539-5545.
62. DeClerck YA, Yean T-D, Chan D, Shimada H, Langley KE. Inhibition of tumor invasion of smooth muscle cell layers by recombinant human metalloproteinase inhibitor. Cancer Res. 1991;51:2151-2157.
63. Schnaper HW, Grant DS, Stetler-Stevenson WG, Fridman R, D'Orazi G, Murphy AN, Bird RE, Hoythya M, Fuerst TR, French DL, Quigley JP, Kleinman HK. Type IV collagenase(s) and TIMPs modulate endothelial cell morphogenesis in vitro. J Cell Physiol. 1993;156:235-246.
64. Murphy AN, Unsworth EJ, Stetler-Stevenson WG. Tissue inhibitor of metalloproteinases-2 inhibits bFGF-induced human microvascular endothelial cell proliferation. J Cell Physiol. 1993;157:351-358.
65. Moses MA, Langer R. A metalloproteinase inhibitor as an inhibitor of neovascularization. J Cell Biochem. 1991;47:230-235.
66. Gavrilovic J, Hembry RM, Reynolds JJ, Murphy G. Tissue inhibitor of metalloproteinases (TIMP) regulates extracellular type I collagen degradation by chondrocytes and endothelial cells. J Cell Sci. 1987;87:357-362.
67. Schneiderman J, Sawdey MS, Keeton MR, Bordin GM, Bernstein EF, Dilley RB, Loskutoff DJ. Increased type 1 plasminogen activator inhibitor gene expression in atherosclerotic human arteries. Proc Natl Acad Sci U S A. 1992;89:6998-7002.
68. Smokovitis A, Kokolis N, Alexaki-Tzivanidou E. Fatty streaks and fibrous plaques in human aorta show increased plasminogen activator activity. Haemostasis. 1988;18:146-153.
69. Forough R, Hasenstab D, Zempo N, Langley K, DeClerck Y, Clowes AW. Induction of tissue inhibitor of metalloproteinase-2 in injured rat artery. Ann N Y Acad Sci. 1994;732:384-388.